Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

The Association Between Increment of Interleukin-1 and Interleukin-6 in Women with Polycystic Ovary Syndrome and Body Mass Index

Authors
1 Department of Clinical Biochemistry, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran; Students Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
2 Endometrium and Endometriosis Research Center, Hamadan University of Medical Sciences, Hamadan, Iran; Department of Obstetrics and Gynecology, Medicine School, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract
Background: There is an association between inflammatory factors and polycystic ovary syndrome (PCOS) and most of women with PCOS experience the symptoms of hirsutism. The purpose of this study was to evaluate the role of obesity in PCOS occurrence, which is linked with inflammation and hirsutism. Methods: This study was designed as a case-control research. It was performed on 102 women with PCOS and 102 healthy women as controls who were age-matched. Serum concentrations of testosterone, estradiol (E2), IL-1, IL-6, high-sensitivity c-reactive protein (hs-CRP), and aromatase activity were measured in blood samples. Statistical tests including unpaired t-tests, Mann-Whitney U test, Kruskal-Wallis, Spearman’s correlation, and Chi-square tests were used for data analysis. Statistical significance was set at p<0.05. Results: A significant difference was found between hs-CRP, IL-1, and IL-6 in PCOS patients and healthy individuals (p<0.001). Aromatase activity was markedly lower in PCOS cases. The serum level of IL-1 (p=0.392) and IL-6 (p=0.764) was not different between overweight and normal weight women. In both studied groups (case and control), hirsutism frequency was markedly higher in individuals with BMI ≥25 kg/m 2 (p<0.05). Inflammatory factors significantly affected the PCOS group (p<0.05). However, logistic regression showed that hs-CRP increment is more effective on increasing the risk of PCOS (OR: 6.324, p<0.001). Conclusion: In this study, hs-CRP, IL-1, and IL-6 levels increased in all PCOS women. Although the incidence of hirsutism in PCOS is associated with obesity, in PCOS pathogenesis, only IL-1 and IL-6 were independent of BMI.
Keywords

  1. Eiras MC, Pinheiro DP, Romcy KAM, Ferriani RA, Reis RMD, Furtado CLM. Polycystic ovary syndrome: the epigenetics behind the disease. Reprod Sci. 2022;29(3):680-94.
  2. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071-e83.
  3. Mancini A, Bruno C, Vergani E, d’Abate C, Giacchi E, Silvestrini A. Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights. Int J Mol Sci. 2021;22(4):1667.
  4. Kordestani F, Mazloomi S, Mortazavi Y, Mazloomzadeh S, Fathi M, Rahmanpour H, et al. Preliminary study showing no association between G238A (rs361525) tumor necrosis factor-α (TNF-α) gene polymorphism and its serum level, hormonal and biochemical aspects of polycystic ovary syndrome. BMC Med Genet. 2018;19(1):149.
  5. Barlampa D, Bompoula MS, Bargiota A, Kalantaridou S, Mastorakos G, Valsamakis G. Hypothalamic inflammation as a potential pathophysiologic basis for the heterogeneity of clinical, hormonal, and metabolic presentation in PCOS. Nutrients. 2021;13(2):520.
  6. Qu X, Donnelly R. Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome. Int J Mol Sci. 2020;21(21):8191.
  7. Goswami S, Choudhuri S, Bhattacharya B, Bhattacharjee R, Roy A, Mukhopadhyay S, et al. Chronic inflammation in polycystic ovary syndrome: A case–control study using multiple markers. Int J Reprod Biomed. 2021;19(4):313-20.
  8. Zangeneh FZ, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed. 2017;15(6):375-82.
  9. Silva JR, Lima FE, Souza AL, Silva AW. Interleukin-1β and TNF-α systems in ovarian follicles and their roles during follicular development, oocyte maturation and ovulation. Zygote. 2020;28(4):270-7.
  10. Mizgier M, Jarząbek-Bielecka G, Wendland N, Jodłowska-Siewert E, Nowicki M, Brożek A, et al. Relation between inflammation, oxidative stress, and macronutrient intakes in normal and excessive body weight adolescent girls with clinical features of polycystic ovary syndrome. Nutrients. 2021;13(3):896.
  11. Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020;34(6):849-63.
  12. Alissa EM, Algarni SA, Khaffji AJ, Al Mansouri NM. Role of inflammatory markers in polycystic ovaries syndrome: in relation to insulin resistance. J Obstet Gynaecol Res. 2021;47(4):1409-15.
  13. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789.
  14. Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HE-D, Amer S. The role of chronic inflammation in polycystic ovarian syndrome—a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):2734.
  15. Fouani FZ, Fadaei R, Moradi N, Zandieh Z, Ansaripour S, Yekaninejad MS, et al. Circulating levels of meteorin-like protein in polycystic ovary syndrome: a case-control study. PloS One. 2020;15(4):e0231943.
  16. Sharifi F, Mazloomi S, Mousavinasab N. High serum ferritin concentrations in polycystic ovary syndrome is not related to insulin resistance. Iran J Diabet Obes. 2011;3(2):47-53.
  17. Karoli R, Fatima J, Siddiqi Z, Vatsal P, Sultania AR, Maini S. Study of early atherosclerotic markers in women with polycystic ovary syndrome. Indian J Endocrinol Metab. 2012;16(6):1004-8.
  18. Acconcia F, Marino M. Steroid hormones: Synthesis, secretion, and transport. Endocrinology: Principles of endocrinology and hormone action Springer Open Books Edn. 2016.
  19. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev. 2022;43(1):91-159.
  20. Yuxin L, Chen L, Xiaoxia L, Yue L, Junjie L, Youzhu L, et al. Research progress on the relationship between obesity-inflammation-aromatase axis and male infertility. Oxid Med Cell Longev. 2021;2021:6612796.
  21. Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018;97(10):1162-7.
  22. Coradini D, Oriana S. Impact of sex hormones dysregulation and adiposity on the outcome of postmenopausal breast cancer patients. Clin Obes. 2021;11(1):e12423.
  23. Trenti A, Tedesco S, Boscaro C, Trevisi L, Bolego C, Cignarella A. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle. Int J Mol Sci. 2018;19(3):859.
  24. Kolanska K, Alijotas‐Reig J, Cohen J, Cheloufi M, Selleret L, D’argent E, et al. Endometriosis with infertility: a comprehensive review on the role of immune deregulation and immunomodulation therapy. Am J Reprod Immunol. 2021;85(3):e13384.
  25. Prins JR, Gomez-Lopez N, Robertson SA. Interleukin-6 in pregnancy and gestational disorders. J Reprod Immunol. 2012;95(1-2):1-14.
  26. Krouni A, Forouhari S, Namavarjahromi B, Dabbaghmanesh MH, Shayan A, Sepasi S, et al. The evaluation of the relationship between some related hormone levels and diet in obese or overweight patients with hirsutism: a randomized clinical trial. J Family Med Prim Care. 2017;6(4):755-9.
  27. Bode D, Seehusen DA, Baird D. Hirsutism in women. Am Fam Physician. 2012;85(4):373-80.
  28. Bakry OA, Al Gayed EM, Seadan AG. Assessment of obesity, dyslipidemia, and insulin resistance in idiopathic hirsutism: a case–control study. J Egyptian Women Dermatol Soci. 2020;17(2):113.
  29. Lumezi BG, Berisha VL. Investigation of body mass index, insulin resistance and diabetes in patients with hirsutism. Postepy Dermatol Alergol. 2021;38(6):1006-10.
  30. Guo R, Zheng Y, Yang J, Zheng N. Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015;16(1):5.
  31. Broekmans FJ, Knauff EAH, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BCJM. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210-7.
  32. Ożga K, Krzyczkowska-Sendrakowska M, Hubalewska-Dydejczyk A, Gilis-Januszewska A, Ratajczak M, Ratajczak M, et al. The value of the free androgen index depends on the phenotype of polycystic ovary syndrome-a single-centre experience. Endokrynol Pol. 2019;70(4):330-5.
  33. Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med. 2019;10:86.
  34. Kałużna M, Człapka-Matyasik M, Wachowiak-Ochmańska K, Moczko J, Kaczmarek J, Janicki A, et al. Effect of central obesity and hyperandrogenism on selected inflammatory markers in patients with PCOS: a WHtR-matched case-control study. J Clin Med. 2020;9(9):3024.
  35. Rostamtabar M, Esmaeilzadeh S, Tourani M, Rahmani A, Baee M, Shirafkan F, et al. Pathophysiological roles of chronic low‐grade inflammation mediators in polycystic ovary syndrome. J Cell Physiol. 2021;236(2):824-38.
  36. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clinl Endocrinol Metab. 2001;86(6):2453-5.
  37. Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, Janowska J, Kocełak P, Madej P, et al. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol. 2007;133(2):197-202.
  38. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048-58.e2.
  39. Alissa EM, Algarni SA, Khaffji AJ, Al Mansouri NM. Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome. J Obstet Gynaecol. 2020;40(8):1133-7.
  40. Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC. Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. J Reprod Immunol. 2007;73(2):188-93.
  41. Garcia‐Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol. 2008;20(6):705-12.
  42. Mahmoudi F, Bayrami A, Zahri S. Influences of L-DOPA and blocking dopamine receptors on aromatase gene expression and serum concentration of LH in rat model of polycystic ovary syndrome. J Fasa Univ Med Sci. 2020;10(3):2448-55.
  43. Herrmann M, Schölmerich J, Straub R. Influence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular data collection. Ann N Y Acad Sci. 2002;966:166-86.
  44. Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod. 1998;4(1):1-8.
  45. Liu T, Huang Y, Lin H. Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells. Int J Mol Med. 2021;47(5):73.
  46. Dhahaad HA, Al-Saadi WT. Correlation study of aromatase, some sex hormones, and body mass index among Iraqi patients with polycystic ovary syndrome. Ann Tropic Med Public Health. 2020;23(18):1-8.
  47. Chen J, Shen S, Tan Y, Xia D, Xia Y, Cao Y, et al. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. J Ovarian Res. 2015;8:11.
  48. Barber TM, McCarthy MI, Wass JAH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137-45.